Combination Products: FDA and EU Regulation of Drug-Device Products

Prefilled syringes, autoinjectors, inhalers, drug-eluting stents and drug-coated balloons all share one regulatory challenge: they combine a drug, a device or a biological product, and each part brings its own rules. Combination products are among the most complex products to take to market because two or more regulatory frameworks apply at once, often with different review teams, different quality systems and different timelines. This guide explains how combination products are defined and assigned in the United States, how the EU treats drug-device combinations, and how to plan development so the two sets of expectations do not collide.

What counts as a combination product

In the US, 21 CFR Part 3 defines a combination product as a product made of two or more regulated components (drug and device, biologic and device, drug and biologic, or all three) in one of several forms:

• Single-entity: the components are physically, chemically or otherwise combined into one product, such as a drug-eluting stent or a prefilled autoinjector.
• Co-packaged: separate products are packaged together, such as a convenience kit containing a drug and a delivery device.
• Cross-labeled: separately provided products are labeled for use together, where the label of each is needed for the intended use or effect, such as a light source used with a photosensitising drug.

The intended use and labeling decide the classification of the product as a combination product, not just how it looks.

United States: primary mode of action and lead center

FDA assigns each combination product to a lead center based on its primary mode of action (PMOA): the single mode of action that provides the most important therapeutic action. If the main therapeutic effect comes from the drug, the Center for Drug Evaluation and Research (CDER) usually leads; if it comes from the device function, the Center for Devices and Radiological Health (CDRH) leads; for biologics, the Center for Biologics Evaluation and Research (CBER) may lead. The lead center decides the type of marketing application (for example an NDA, a BLA, a PMA or a 510(k)), and consults the other centers on their component.

If the assignment is unclear, a sponsor can file a Request for Designation (RFD) with the Office of Combination Products. FDA aims to respond within 60 days of filing. You can also seek informal feedback early through a pre-submission discussion; see our guide to FDA Pre-Submission meetings.

United States: quality system requirements

A combination product must meet the current good manufacturing practice (CGMP) requirements for each of its constituent parts. 21 CFR Part 4, Subpart A, sets out how to do this efficiently. A manufacturer can follow the drug CGMPs (21 CFR Parts 210 and 211) or the device quality system requirements as a base, and then show compliance with a defined list of additional provisions from the other set, for example design controls and purchasing controls when starting from drug CGMPs. Since the Quality Management System Regulation took effect on 2 February 2026, device quality requirements are based on ISO 13485:2016, so confirm how the current rule text and FDA’s combination product guidance map the “streamlined approach” onto your quality system.

The same logic applies to design: even where the lead center is not CDRH, the device constituent part needs design controls, risk management and usability evidence. See design controls for medical devices.

United States: postmarket safety reporting

21 CFR Part 4, Subpart B, sets postmarket safety reporting requirements for combination product applicants. In summary, the applicant must follow the reporting rules for the constituent part that is the basis of the application, plus extra reporting obligations arising from the other constituent parts. In practice that means building a complaint and adverse event process that can capture both drug and device signals and route them to the right report type. Read this alongside our guides on complaint handling and recalls and field actions.

European Union: how combinations are regulated

The EU does not use a single “combination product” category. Instead, the legal route depends on how the product is presented and how it works.

Situation	Governing law	What it means in practice
Device that incorporates, as an integral part, a medicinal substance acting on the body with action ancillary to the device	MDR (device), with a medicines authority consulted	Notified body consults a medicines authority or the EMA on the quality, safety and usefulness of the substance. Such devices are typically high-risk.
Integral drug-device product, where the device and medicine form a single product intended exclusively for use in that combination and not reusable	Medicines legislation (Directive 2001/83/EC or Regulation 726/2004)	The medicine’s marketing authorisation covers the product. The device part must still meet the MDR general safety and performance requirements (Annex I). The medicines authority expects a notified body opinion or a CE certificate for the device part.
Separate drug and device that are co-packaged or used together but not integral	Each under its own law	The device is CE marked under the MDR and the drug has its own authorisation, with compatibility shown between them.

The EMA and the European Commission have published guidance on the quality documentation expected for the device part of integral combinations, so check the latest versions when planning. Because notified body capacity for these opinions is limited, engage early. For the wider EU picture see EU MDR and IVDR explained.

A practical development approach

1. Decide the regulatory classification early. Document the PMOA (US) and the integral or non-integral status (EU) before design freeze.
2. Agree a development plan across functions. Combine drug, device, clinical and regulatory plans so that, for example, device verification and drug stability studies are scheduled together.
3. Use one integrated risk management file. Link drug-related hazards (dose accuracy, extractables, interactions) with device-related hazards (use errors, mechanical failure). See risk management for medical devices.
4. Treat human factors as central. Delivery devices are used by patients and lay users, so usability evidence is often decisive. Our guide to usability engineering covers the method.
5. Plan stability, sterilization and packaging together. Drug-contact materials, container closure integrity and shelf life interact with sterilization and packaging validation and biocompatibility.
6. Control suppliers and changes across both sides. A change to a device component can affect drug delivery and vice versa, so route changes through a joint change control.

Common mistakes

• Assuming the device team’s quality system alone is enough, without mapping drug CGMP requirements.
• Choosing a pathway before confirming the PMOA or the EU integral status.
• Running drug stability and device verification on different timelines, so a late result forces a redesign.
• Neglecting human factors for self-administered products.
• Building separate complaint systems for the drug and device sides that never reconcile.
• Not allowing time for the extra consultation steps, such as a notified body opinion or inter-center consults.

Frequently asked questions

What is the primary mode of action?

It is the single mode of action of a combination product that provides the most important therapeutic action of the product. It determines which FDA center leads the review and which type of marketing application applies.

Can a combination product need both an NDA and a 510(k)?

Usually one marketing application, reviewed by the lead center with input from the others, is enough. In some cases, such as separately provided products, more than one application may be needed, so confirm with FDA.

Does the EU have a combination product regulation?

No single regulation. The route depends on whether the drug and device are integral, and on whether the medicinal substance acts in an ancillary way. The MDR and medicines legislation interact through consultation and notified body opinion requirements.

Do prefilled syringes count as combination products?

In the US, a prefilled syringe containing a drug is generally a single-entity combination product, typically led by the drug center. In the EU, it is typically an integral product governed by medicines law, with the device part meeting MDR Annex I requirements.

Combination product policy and guidance are updated often. Confirm current requirements with FDA, the EMA and your notified body or medicines authority before finalising your regulatory plan.

Related reading

• US FDA medical device regulations: classification, pathways and QMSR.
• Medical device classification under FDA and the EU MDR: how risk class drives the route.
• Medical device regulatory strategy: planning evidence and market sequence.
• Pharmacovigilance course: safety reporting skills for drug and device teams.

Talk to the AptSkill team

Working on a drug-device product and need regulatory or safety training? Send us your role and goal.